Experience of using ademethionin in treatment of patients with non-alcoholic fatty liver disease

Abstract

The incidence of non-alcoholic fatty liver disease (NAFLD) in the Russian Federation is increasing rapidly in proportion to the increase in the number of patients with obesity, hypertension, dyslipidemia, diabetes mellitus, et al. The incipient and often asymptomatic disease progresses, which forms the basis for numerous threatening complications. What modern therapeutic tools to reduce the degree of liver disease activity and prevent the development of complications do the gastroenterologists have? We are talking about this with the Honoured Doctor of the Russian Federation, the leading researcher of the Department of Endocrine and Metabolic Disorders of the Moscow Clinical Research and Practical Center, Doctor of Medicine, Professor Larisa Arsentievna Zvenigorodskaya.